Pursuant to Regulation 30 and Regulation 33 of the SEBI (LODR) Regulations, 2015, this is to inform you that the Board of Directors at its meeting held on Thursday, 12th February, 2026, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivanza Biosciences reported standalone revenue of Rs 4,493.26 lakhs for Q3 FY26, a sharp jump from Rs 76.21 lakhs in the year-ago quarter. For the nine months ended December 2025, standalone revenue surged to Rs 10,648.51 lakhs (vs Rs 276.47 lakhs in 9M FY25). The company returned to profitability with a nine-month PAT of Rs 64.12 lakhs versus Rs 28.08 lakhs a year ago, a turnaround from the Rs 69.51 lakh loss reported in full-year FY25. However, profit margins remain razor-thin at around 0.36% in Q3 versus nearly 5% a year ago, indicating heavy margin compression despite the topline surge. Consolidated nine-month revenue stood at Rs 10,954.77 lakhs with PAT of Rs 84.52 lakhs. The statutory auditor's limited review report was clean, with no qualifications or adverse observations.
The revenue surge and return to profit may lift short-term sentiment, but the steep margin compression signals that growth is low-margin and volume-driven. Shareholders should watch whether margins can recover, as headline topline growth alone may not translate into sustained earnings improvement.